



## Supplementary Figure 1




Supplementary figure 1: (A) Immunohistochemical analysis of E-cadherin, N-cadherin, and vimentin in lung tissues and quantitative statistics of each group. (B) RT-qPCR analysis of the mRNA level of miR-23b-5p from the lung of mice. (C) CCK8 test of BEAS-2B transfected with miR-23b-3p mimic or miR-23b-3p inhibitor with or without TGF-β1 treatment in 5 days. (D) Flow cytometry analysis of apoptosis of BEAS-2B transfected with miR-23b-3p mimic or miR-23b-3p inhibitor with or without TGF-β1 treatment. The results are presented as the means  $\pm$  SD of three independent experiments. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  compared with the indicated groups.

Supplementary Figure 2



Supplementary figure 2: Genomic structure and distribution of miR-23b-3p CpG dinucleotides over the transcription start site (TSS).

Supplementary Figure 3



Supplementary figure 3: (A) mmu-miR-23b-3p and has-miR-23b-3p were both directly targeted PTEN with same binding site. (B) Dual-luciferase reporter assay. The relative luciferase activity was normalized to the renilla luciferase activity assay after cotransfection with the miR-23b-3p mimic and miR-RB-REPORT constructs containing WT or MUT PTEN 3'UTR region in 293T cell lines.

Supplementary Table 1: Primer sequences applied for gene expression analyses

species	gene	Forward primer	Reversed primer
human	E-cadherin	ATTTTCCCTCGACACCCGAT	TCCCAGGCGTAGACCAAGA
	N-cadherin	TCAGGCGTCTGTAGAGGCTT	ATGCACATCCTTCGATAAGACTG
	Vimentin	AGTCCA CTGTACCGGAGAC	CATTTACGCATCTGGCGTTC
	$\beta$ -actin	CATGTACGTTGCTATCCAGGC	CTCCTTAATGTCACGCACGAT
	PTEN	TGGATTGACTTAGACTTGACCT	GGTGGGTTATGGTCTCAAAGG
	DNMT1	CCTAGCCCCAGGATTACAAGG	ACTCATCCGATTTGGCTCTTTC
	DNMT3a	CCGATGCTGGGGACAAGAAT	CCCATCATCCACCAAGACAC
	DNMT3b	CCCAGCTCTTACCTTACCATCG	GGTCCCCTATTCCAAACTCCT
	miR-23b-3p RT	CTCAACTGGTGTCTGGAGTCGGCAATTCAGTTGAGGTAGTAAT	
	miR-23b-3p	ACACTCCAGCTGGGATCACATTGCCAGGGAT	TGGTGTCTGGAGTCTG
U6	CTCGCTTCGGCAGCACA	AACGCTTCACGAATTTGCGT	
mouse	E-cadherin	CAGTTCGAGGTCTACACCTT	TGAATCGGGAGTCTTCCGAAAA
	N-cadherin	AGCGCAGTCTTACCGAAGG	TCGCTGCTTTCATACTGAACTTT
	Vimentin	CGTCCACACGCACCTACAG	GGGGGATGAGGAATAGAGGCT
	$\beta$ -actin	GGCTGTATTCCCCTCCATCG	CCAGTTGGTAACAATGCCATGT
	PTEN	TGGATTGACTTAGACTTGACCT	GCGGTGTCATAATGTCTCTCAG
	DNMT1	CCGTGGCTACGAGGAGAAC	TTGGGTTTCCGTTTAGTGGGG
	DNMT3a	GATGAGCCTGAGTATGAGGATGG	CAAGACACAATTCGGCCTGG
	DNMT3b	CGTTAATGGGAACCTCAGTGACC	CTGCGTGTAATTCAGAAGGCT
	miR-23b-3p RT	CTCAACTGGTGTCTGGAGTCGGCAATTCAGTTGAGGGTAATCC	
	miR-23b-3p	ACACTCCAGCTGGGTGGGTTCCCTGGCATGC	TGGTGTCTGGAGTCTG
U6	CTCGCTTCGGCAGCACA	AACGCTTCACGAATTTGCGT	